Washington, D.C. 20549

May 11, 2022
Commission File No. 001-34269

(Exact Name Of Registrant As Specified In Its Charter)

(State Or Other Jurisdiction Of
Incorporation Or Organization)

(IRS Employer
Identification No.)
9220 Kirby Drive, Suite 500
Houston, Texas 77054
(Address Of Principal Executive Offices)

Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of Each ClassTrading SymbolName of Each Exchange on Which Registered
Common Shares, $0.01 Par ValueSMEDThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is a an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 2.02    Disclosure of Results of Operations and Financial Condition

Item 9.01    Financial Statements and Exhibits



        Press Release

Item 2.02. Results of Operations and Financial Condition.
On May 11, 2022, Sharps Compliance Corp. (the "Company") announced its results of operations for the three and nine months ended March 31, 2022. A copy of the earnings release is attached as Exhibit 99.1.
The information in this Current Report is being furnished pursuant to Item 2.02 including Exhibit 99.1 of Form 8-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), and Section 11 of the Securities Act of 1933, as amended, otherwise subject to the liabilities of those sections nor incorporated by reference in any filing under the Exchange Act unless specifically referenced in such subsequent filing as being incorporated by reference. The Company does not undertake a duty to update the information in this Current Report and cautions that the information included in this Current Report is current only as of May 11, 2022 and may change thereafter.

Item 9.01. Financial Statements and Exhibits.
(a)Financial Information
    Not applicable.
(b) Pro Forma Financial Information
    Not applicable.
Exhibit        Description
Press Release, dated May 11, 2022.


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 11, 2022

Diana P. Diaz
Senior Vice President and Chief Accounting Officer


Exhibit Number            

EX-99.1 2 ex991-sharpscomplianceq3fy.htm EX-99.1 Document

Sharps Compliance Reports Fiscal 2022 Third Quarter Results

Third quarter revenue of $17.6 million decreased 36% compared to the prior year; Excluding COVID-19 related immunization activity, third quarter revenue increased 24%
Route-based customer locations increased 21% to 18,600 from 15,400 in the prior year; billings increased 12%
Professional market billings grew 19% compared to prior year third quarter
Home Healthcare billings increased 21% compared to third quarter 2021
Third quarter immunization-related mailback billings of $2.9 million decreased as compared to $20.2 million in third quarter 2021; Increased substantially over pre-COVID levels of $0.7 million in third quarter 2020
MedSafe billings increased 19% to $1.5 million from $1.2 million in the prior year period, consistent with a 20% increase in MedSafe liners shipped and a 19% increase in MedSafe liners returned
Closed on Midwest Medical Waste Inc. acquisition on February 4, 2022
Cash balance of $26.7 million at March 31, 2022

HOUSTON, Texas, May 11, 2022 - Sharps Compliance Corp. (NASDAQ: SMED) (“Sharps” or the “Company”), a leading full-service national provider of comprehensive waste management solutions including medical, pharmaceutical and hazardous, today reported financial results for the third quarter of fiscal 2022, ended March 31, 2022.

Revenue in the third quarter of fiscal 2022 was $17.6 million, a decrease of 36% compared to $27.5 million in the same prior year quarter. Excluding COVID-19 related immunization and testing revenue of $4.3 million in the third quarter of fiscal 2022 and $16.8 million in the prior year period, revenue increased 24% compared to the prior year period. Customer billings of $17.1 million decreased 45% compared to $31.0 million for the same prior year quarter. Immunization-related mailback billings were $2.9 million in the third quarter of fiscal 2022 compared to $20.2 million in the prior year period. Excluding COVID-19 related immunization mailbacks, customer billings increased 31% compared to the prior year period. Third quarter 2022 gross margin was 28% as compared to gross margin of 49% in the third quarter of 2021. SG&A increased by approximately $0.5 million or 13% to $4.7 million in the third quarter of fiscal 2022, compared to the same prior year quarter. The increase in SG&A is related primarily to $0.2 million in acquisition related costs, $0.1 million in management transition costs and continued investment in sales and marketing.

The Company reported near breakeven operating income in the third quarter of 2022, compared to operating income of $9.0 million in the third quarter of 2021. Sharps recorded a net loss of $0.3 million, or ($0.01) per basic and diluted share, in the third quarter of fiscal 2022, as compared to net income of $6.9 million, or $0.41 per basic and $0.40 per diluted share in the third quarter of fiscal 2021. Sharps reported EBITDA of $0.7 million in the third quarter of fiscal 2022 compared to EBITDA of $9.6 million in the third quarter of fiscal 2021. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release).

Pat Mulloy, President and Chief Executive Officer of Sharps, stated, “Our third quarter results are largely in line with our expectations and reflect a return to more normalized market conditions following unusually strong performance in the March quarter of fiscal 2021, which benefitted significantly from COVID-19 immunization activity. March has historically been our slowest revenue quarter, due to seasonality and customer ordering patterns, and we are pleased that third quarter 2022 revenue of $17.6 million showed a significant increase as compared to third quarter fiscal 2020 pre-COVID revenue of $10.4 million. Gross margin of 28% was lower than anticipated primarily due to higher costs related to: hiring additional operating personnel to meet increased demand, which required increased wages to match market conditions and higher fuel costs associated with our route-based business. During the quarter, the Company implemented a number of customer price increases designed to cover the heightened costs of providing our solutions and services, however, those increases were not yet fully reflected in revenue during the third quarter of fiscal 2022. We expect that the full impact of our cost mitigation initiatives will alleviate potential continued cost increases going forward.

“As we continue to establish Sharps as a leading and comprehensive provider of medical, pharmaceutical and hazardous waste management solutions, we are growing our route-based footprint, and we’re pleased to have achieved a 12% increase in route-based billings in the third quarter, directly related to continued demand for our solution offerings across the markets we serve. We saw particular strength from the Professional market, where billings increased 19% in the third quarter. In our route-based business, we’re pleased to report we have completed the integration of Midwest Medical, a full-service, route-based provider of medical and hazardous waste solutions serving about 600 customer locations across Kansas, strengthening our foothold in the region. Our MedSafe remains well positioned as an effective solution to address the tremendous market opportunity related to the safe, cost-efficient and DEA compliant disposal of unused medications. We are focused on our continued rollout of MedSafe to retail pharmacies as well as the long-term care market and as we previously discussed, during the quarter we announced a partnership with PharMerica, a nationwide leader in long-term care pharmacy services, and look forward to working with them and other long term care pharmacies to solve a complex problem.”

Mr. Mulloy concluded, “It is increasingly apparent to me since being appointed CEO in early April, that there is a huge opportunity to truly scale our business, both organically and through our strategic acquisition strategy. We are intent on growing our leadership position as a comprehensive provider of medical waste solutions for the population of small to medium quantity generators we serve, and believe we have the people, products and infrastructure to continue expanding our geographic reach and to capture additional market share. Furthermore, our acquisition pipeline is robust, which we expect will offer additional opportunities for us to strengthen our route-based offering.”

Third Quarter Review

Professional market billings increased 19% to $5.5 million in the third quarter of fiscal 2022 as compared to $4.6 million in the third quarter of 2021 consistent with the increase in route-based customer locations.

Retail market billings decreased 79% to $4.6 million in the third quarter of fiscal 2022 as compared to $21.7 million in the same prior year period. Within the retail market, immunization related orders were down significantly at $2.9 million in the third quarter of fiscal 2022 compared to $20.2 million in the same prior year period. As noted above, immunization activity in the third quarter of 2021 was very strong related to the initial availability of the COVID-19 vaccine to the broader public in the U.S. Compared to the pre-COVID third quarter of fiscal 2020, retail market billings increased 98% from $2.3 million reflecting an increase in immunization and testing related orders of over 340% from $0.7 million in the third quarter of fiscal 2020.

Pharmaceutical Manufacturer market billings increased by $1.9 million, or 341% to $2.5 million in the third quarter of fiscal 2022 as compared to $0.6 million in the same prior year period due to the timing of inventory builds for patient support programs.

Long-Term Care billings decreased 10% to $0.9 million in the third quarter of fiscal 2022 compared to $1.0 million in the prior year period, related primarily to heightened volumes of COVID-19 related waste management in the prior year, most of which impacted the route-based business customer billings.

Home Health Care market billings increased 21% to $2.8 million in the third quarter of fiscal 2022 compared to $2.3 million in the third quarter of fiscal 2021, driving most of the $0.9 million increase in billings for other (non-mailback) solutions.

Billings for Unused Medications of $2.1 million in the third quarter of fiscal 2022 were essentially flat as compared to $2.1 million in the same prior year period. Within the Unused Medications category, MedSafe billings increased 19% to $1.5 million from $1.2 million in the prior year period, consistent with a 20% increase in MedSafe liners shipped and a 19% increase in MedSafe liners returned for processing. The increase in MedSafe billings was mostly offset by a decrease in TakeAway envelope sales due to higher-than-normal sales in the prior year quarter.

First Nine Months Fiscal 2022 Results

Sharps recorded revenue of $50.4 million in the first nine months of fiscal 2022, a decrease of 13% compared to revenue of $57.7 million in the first nine months of fiscal 2021. Customer billings decreased 26% to $46.8 million for the first nine months of fiscal 2022. Professional market billings increased 15% to $15.2 million in the first nine months of fiscal 2022 as compared to $13.3 million in the same prior year period. Retail market billings decreased 53% to $14.8 million as compared to $31.5 million in the first nine months of fiscal 2021, with billings for flu shot / COVID-19 related orders decreasing to $9.3 million compared to $26.6 million in the first nine months in the prior year related to lower immunization and testing activity in the current year as described above. Long-Term Care market billings decreased 28% to $2.4 million as compared to $3.3 million in the prior year period related primarily to heightened volumes of COVID-19 related waste management in the prior year, most of which impacted the route-based business customer billings. During the first nine months of fiscal 2022, Pharmaceutical Manufacturer market billings increased 2% to $4.9 million as compared to $4.8 million in the first nine months of fiscal 2021. Home Health Care market billings decreased 10% to $6.8 million for the first nine months of fiscal 2022 compared to $7.5 million in the first nine months of 2021 due to the timing of distributor orders.

The 5% increase in route-based pickup revenue to $10.8 million was negatively impacted by heightened volumes of COVID-19 related waste management in the prior year in long-term care of about $0.6 million and in the professional market for labs of about $0.2 million. Route-based revenue generated by our acquired businesses accounted for $0.6 million of revenue. Excluding the prior year COVID-19 bump and the positive impact of the acquired businesses, organic route-based business increased 9%, consistent with the growth in organic customer locations of 13%. Unused medications billings increased 7% to $6.6 million as compared to $6.2 million in the first nine months of fiscal 2021. Within unused medications, MedSafe billings increased 20% to $4.7 million consistent with a 27% increase in MedSafe liners shipped and a 26% increase in MedSafe liners returned for processing.

Gross margin was 26% for the first nine months of fiscal 2022 as compared to 39% in first nine months of fiscal 2021. SG&A expense increased 13% to $13.3 million in the first nine months of fiscal 2022 compared to $11.7 million in the first nine months of fiscal 2021, related to $0.4 million in acquisition related costs, $0.1 million in management transition costs, a $0.4 million increase in the accrual of management incentive compensation and the Company’s continued investments in sales and marketing. The Company recorded an operating loss of $0.9 million in the first nine months of fiscal 2022 as compared to operating income of $10.3 million in the first nine months of fiscal 2021.

Net loss for the first nine months of fiscal 2022 was $1.0 million or a net loss of $0.06 per basic and diluted share compared to net income of $7.8 million or $0.47 per basic and $0.46 per diluted share for the first nine months of fiscal 2021.

Sharps recorded EBITDA of $1.0 million in the first nine months of fiscal 2022, as compared to EBITDA of $11.8 million in the first nine months of fiscal 2021. (See Reconciliation of Net Income (Loss) to EBITDA in the supplemental table included at the end of this release).

Financial Flexibility and a Strong Balance Sheet

Cash was $26.7 million at March 31, 2022, compared to cash of $27.8 million at June 30, 2021. The Company had working capital of $37.1 million at March 31, 2022 compared to working capital of $27.9 million at June 30, 2021.

Restatement of Financial Reports for the Periods Ended September 30, 2021 and December 31, 2021

On May 5, 2022, the Audit Committee of the Board of Directors of or the Company concluded that the unaudited consolidated financial statements included in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended September 30, 2021 and December 31, 2021, filed with the Securities and Exchange Commission on November 3, 2021 and February 2, 2022, respectively (the “Initial Filings”), should not be relied upon because the Company had under reported freight costs associated with immunization related mailbacks returned for treatment. This occurred primarily as a result of a misunderstanding with the applicable carrier regarding certain charges for services rendered during these periods.

We intend to file amendments to the Initial Filings in order to restate the unaudited consolidated financial statements as of and for the quarterly and year-to-date periods ended September 30, 2021 and December 31, 2021 (such amendments, the “Amended Filings”).

We anticipate that the amended Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2021 will reflect an increase in operating loss of approximately $0.7 million and an increase in net loss of approximately $0.6 million resulting in a net loss of approximately $1.3 million as compared to a net loss originally reported of approximately $0.8 million.

We anticipate the amended Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2021 will reflect, for the fiscal quarter then ended, a decrease in operating income of approximately $1.2 million and a decrease in net income of approximately $0.9 million, resulting in net income of approximately $0.6 million as compared to net income originally reported of approximately $1.4 million. For the six-month period ended December 31, 2021, we anticipate that there will be a reduction in operating income of approximately $1.9 million and a reduction in net income of approximately $1.4 million, resulting in a net loss of approximately $0.8 million as compared to net income originally reported of approximately $0.6 million.

Previously reported amounts for revenue, total cash flows from operating activities, and net changes in cash and cash equivalents are not affected by the adjustments described above.

The Company’s earnings and press releases and similar communications, to the extent that they relate to our financial statements for the Initial Filings, should no longer be relied upon.

Further details related to the restatement may be found in the Form 8-K filed by the Company today, May 11, 2022.

Third Quarter Fiscal Year 2022 Webcast and Conference Call

The Company will host a teleconference tomorrow, May 12, 2022, beginning at 11:00 a.m. Eastern Time, during which management will review the financial and operating results for the period and discuss Sharps’ corporate strategy and outlook. A question-and-answer session will follow.

The Sharps Compliance conference call can be accessed by domestic callers by dialing (877) 545-0320. International callers may access the call by dialing (973) 528-0002. Callers should use conference entry code 797852. The webcast can be monitored at www.sharpsinc.com.

A telephonic replay will be available through June 11, 2022. To listen to the replay, domestic callers should dial (877) 481-4010 and international callers should dial (919) 882-2331 and enter replay ID number 45246. Transcript will also be posted to the Sharps Compliance website, once available.

About Sharps Compliance Corp.

Headquartered in Houston, Texas, Sharps Compliance (NASDAQ: SMED) is a leading business-to-business services provider to the healthcare, long-term care and retail pharmacy markets. Sharps Compliance offers comprehensive solutions for the management of regulated medical waste, hazardous waste and unused medications. For more information, visit: www.sharpsinc.com.

Forward-Looking Statements

The information made available in this news release contains certain forward-looking statements relating to the Company that are based on the beliefs of the Company’s management as well as assumptions made by and information currently available to the Company’s management. When used in this document, the words "may," “position,” "plan," “potential,” “designed,” “continue,” "anticipate," "believe," "expect," "estimate," “project,” and “intend” and words or phrases of similar import, as they relate to the Company or its subsidiaries or Company management, are intended to identify forward-looking statements. Such statements reflect the known and unknown risks, uncertainties and assumptions related to certain factors including, without limitation, competitive factors, general economic conditions, customer relations, relationships with vendors, governmental regulation and supervision, seasonality, distribution networks, product introductions and acceptance, technological change, changes in industry practices, onetime events and other factors described herein including the impact of the coronavirus COVID-19 (“COVID-19”) pandemic on our operations and financial results. Based upon changing conditions, should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected or intended. Consequently, no forward-looking statements can be guaranteed. When considering these forward-looking statements, you should keep in mind the risk

factors and other cautionary statements in the Company’s Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K, and our other filings with the Securities and Exchange Commission. Actual results may vary materially. You are cautioned not to place undue reliance on any forward-looking statements. You should also understand that it is not possible to predict or identify all such factors and as such should not consider the preceding list or the risk factors to be a complete list of all potential risks and uncertainties. The Company does not intend to update these forward-looking statements.

Non-GAAP Measures

This release contains certain financial information not derived in accordance with generally accepted accounting principles (“GAAP”), including customer billings information and EBITDA. The Company believes this information is useful to investors and other interested parties. EBITDA is a significant performance metric used by management and by external users of our financial statements such as investors, research analysts and others to assess the financial performance of our assets without regard to financing methods, capital structure or historical cost basis; the ability of our assets to generate cash sufficient to pay interest costs and support our indebtedness; and our operating performance and return on capital as compared to those of other companies in our industry. Such information should not be considered as a substitute for any measure derived in accordance with GAAP, or as an alternative to cash flow from operating activities or measure of our liquidity and may not be comparable to other similarly titled measures of other companies. Reconciliation of this information to the most comparable GAAP measures is included as an attachment to this release.

For more information contact:
Pat Mulloy
Sharps Compliance Corp.
Chief Executive Officer and President
Phone: (713) 660-3514
Email: pmulloy@sharpsinc.com
John Nesbett/Jennifer Belodeau
IMS Investor Relations
Phone: (203) 972-9200
Email: sharps@imsinvestorrelations.com


Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Statements of Operations
(in thousands, except per share data)

Three-Months Ended Nine-Months Ended
March 31,March 31,
20222021% Change20222021% Change
Revenue$17,579 $27,528 (36.1)%$50,372 $57,690 (12.7)%
Cost of revenue12,601 14,129 (10.8)%37,266 35,031 6.4 %
Gross profit4,978 13,399 (62.8)%13,106 22,659 (42.2)%
Gross margin28.3 %48.7 %26.0 %39.3 %
SG&A expense4,713 4,181 12.7 %13,301 11,725 13.4 %
Depreciation and amortization272 216 726 625 
Operating Income (Loss)(7)9,002 (921)10,309 
Operating margin0.0 %32.7 %(1.8)%17.9 %
Interest income16 — 30 — 
Interest expense(53)(55)(167)(134)
Income associated with derivative instrument44 26 78 41 
Total other income (expense)(29)(59)(93)
Income (loss) before income taxes— 8,973 (980)10,216 
Income tax expense287 2,123 66 2,431 
Net Income (Loss)$(287)$6,850 $(1,046)$7,785 
Net Income (Loss) Per Share
Basic$(0.01)$0.41 $(0.06)$0.47 
Diluted$(0.01)$0.40 $(0.06)$0.46 
Weighted Average Shares Outstanding
Basic19,412 16,556 18,842 16,481 
Diluted19,412 17,187 18,842 16,978 

Sharps Compliance Corp. and Subsidiaries
Condensed Consolidated Balance Sheets
(in thousands)
March 31,June 30,
Current assets:
Cash$26,744 $27,767 
Accounts receivable, net14,790 9,738 
Inventory6,979 6,114 
Contract asset16 20 
Prepaid and other current assets3,446 1,459 
Total current assets51,975 45,098 
Property, plant and equipment, net11,786 10,843 
Operating lease right of use asset12,424 8,353 
Financing lease right of use asset, net932 907 
Inventory, net of current portion987 989 
Other assets325 110 
Goodwill10,216 6,735 
Intangible assets, net4,541 2,239 
Deferred tax asset, net150 157 
Total assets$93,336 $75,431 
Current liabilities
Accounts payable$3,090 $2,922 
Accrued liabilities4,104 3,940 
Operating lease liability2,872 2,368 
Financing lease liability189 160 
Current maturities of long-term debt307 735 
Contract liability4,285 7,028 
Total current liabilities14,847 17,153 
Contract liability, net of current portion523 1,461 
Operating lease liability, net of current portion9,701 6,118 
Financing lease liability, net of current portion756 741 
Other liabilities— 45 
Long-term debt, net of current portion3,095 3,329 
Total liabilities28,922 28,847 
Stockholders' equity64,414 46,584 
Total liabilities and stockholders' equity$93,336 $75,431 

Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing and Revenue Information
(in thousands)

Three-Months Ended March 31,
2022% Total2021$ Change%
Professional$5,492 32.1 %$4,606 $886 19.2 %
Retail4,575 26.8 %21,714 (17,139)(78.9)%
Home Health Care2,786 16.3 %2,299 487 21.2 %
Pharmaceutical Manufacturer2,503 14.6 %567 1,936 341.4 %
Long-Term Care876 5.1 %973 (97)(10.0)%
Government517 3.0 %642 (125)(19.5)%
Environmental180 1.1 %76 104 136.8 %
Other166 1.0 %131 35 26.7 %
Subtotal17,095 100.0 %31,008 (13,913)(44.9)%
GAAP Adjustment *484 (3,480)3,964 
Revenue Reported$17,579 $27,528 $(9,949)(36.1)%
Nine-Months Ended March 31,
2022% Total2021$ Change%
Professional$15,208 32.5 %$13,277 $1,931 14.5 %
Retail14,807 31.6 %31,500 (16,693)(53.0)%
Home Health Care6,753 14.4 %7,479 (726)(9.7)%
Pharmaceutical Manufacturer4,900 10.5 %4,808 92 1.9 %
Long-Term Care2,406 5.1 %3,342 (936)(28.0)%
Government1,788 3.8 %1,654 134 8.1 %
Environmental265 0.6 %390 (125)(32.1)%
Other692 1.5 %452 240 53.1 %
Subtotal46,819 100.0 %62,902 (16,083)(25.6)%
GAAP Adjustment *3,553 (5,212)8,765 
Revenue Reported$50,372 $57,690 $(7,318)(12.7)%
*Represents the net impact of the revenue recognition adjustments to arrive at reported GAAP revenue. Customer billings include all invoiced amounts for products shipped or services rendered during the period reported. GAAP revenue includes customer billings as well as numerous adjustments necessary to reflect, (i) the deferral of a portion of current period sales, (ii) recognition of certain revenue associated with product returned for treatment and destruction and (iii) provisions for certain product returns and discounts to customers which are accounted for as reductions in sales in the same period the related sales are recorded.

Sharps Compliance Corp. and Subsidiaries
Supplemental Customer Billing by Solution Information
(in thousands)

Three-Months Ended March 31,
2022% Total2021$ Change%
Mailbacks$8,992 52.5 %$24,373 $(15,381)(63.1)%
Route-Based Pickup4,044 23.7 %3,597 447 12.4 %
Unused Medications2,098 12.3 %2,078 20 1.0 %
Third Party Treatment180 1.1 %76 104 136.8 %
Other1,781 10.4 %884 897 101.5 %
Total Billings by Solution$17,095 100.0 %$31,008 $(13,913)(44.9)%
Nine-Months Ended March 31,
2022% Total2021$ Change%
Mailbacks$24,741 52.7 %$42,719 $(17,978)(42.1)%
Route-Based Pickup10,794 23.1 %10,244 550 5.4 %
Unused Medications6,592 14.1 %6,152 440 7.2 %
Third Party Treatment265 0.6 %390 (125)(32.1)%
Other4,427 9.5 %3,397 1,030 30.3 %
Total Billings by Solution$46,819 100.0 %$62,902 $(16,083)(25.6)%

Sharps Compliance Corp. and Subsidiaries
Supplemental Table to Reconcile Net Income (Loss) to EBITDA*
(in thousands)

Three-Months Ended Nine-Months Ended
March 31,March 31,
Net Income (Loss)$(287)$6,850 $(1,046)$7,785 
Income tax expense287 2,123 66 2,431 
Interest expense, net37 55 137 134 
Depreciation and amortization654 522 1,820 1,445 
EBITDA$691 $9,550 $977 $11,795 
*The Company defines earnings before interest, taxes, depreciation and amortization (“EBITDA”) as net income (loss), plus income tax expense, net interest expense, and depreciation and amortization. Other companies may define EBITDA differently. EBITDA is presented because it is a financial measure that is frequently requested by third parties. However, EBITDA is not considered under generally accepted accounting principles as a primary measure of an entity’s financial results, and accordingly, EBITDA should not be considered an alternative to operating income, net income, or cash flows as determined under generally accepted accounting principles and as reported by the Company.

EX-101.SCH 3 smed-20220511.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 smed-20220511_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 5 smed-20220511_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 11, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 11, 2022
Entity File Number 001-34269
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 74-2657168
Entity Address, Address Line One 9220 Kirby Drive
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77054
City Area Code 713
Local Phone Number 432-0300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, $0.01 Par Value
Trading Symbol SMED
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000898770
Amendment Flag false
XML 7 smed-20220511_htm.xml IDEA: XBRL DOCUMENT 0000898770 2022-05-11 2022-05-11 0000898770 false 8-K 2022-05-11 SHARPS COMPLIANCE CORP 001-34269 DE 74-2657168 9220 Kirby Drive Suite 500 Houston TX 77054 713 432-0300 false false false false Common Shares, $0.01 Par Value SMED NASDAQ false 2022-05-11 2022-05-11 2022-05-11 2022-05-11 EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Document and Entity Information Sheet http://sharpsinc.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports smed-20220511.htm ex991-sharpscomplianceq3fy.htm smed-20220511.xsd smed-20220511_lab.xml smed-20220511_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "smed-20220511.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "smed-20220511.htm" ] }, "labelLink": { "local": [ "smed-20220511_lab.xml" ] }, "presentationLink": { "local": [ "smed-20220511_pre.xml" ] }, "schema": { "local": [ "smed-20220511.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "smed", "nsuri": "http://sharpsinc.com/20220511", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "smed-20220511.htm", "contextRef": "i1920aa941c514e5583a928bd89f4b483_D20220511-20220511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Document and Entity Information", "role": "http://sharpsinc.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "smed-20220511.htm", "contextRef": "i1920aa941c514e5583a928bd89f4b483_D20220511-20220511", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://sharpsinc.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0000898770-22-000033-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000898770-22-000033-xbrl.zip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end